Gil Morgan MD
@weoncologists.bsky.social
1.8K followers 720 following 50 posts
Clinical Oncologist from Texas🇺🇸 @oncoalert.bsky.social Representative 🚨 Proudly NIH, NCI & MDA trained. An ounce of prevention equals a pound of cure. Views are own🌏
Posts Media Videos Starter Packs
Reposted by Gil Morgan MD
oncoalert.bsky.social
The OncoAlert Breast Cancer Faculty, led by Dr. Elisa Agostinetto🇧🇪 , has selected the OncoAlert🚨 TOP 🔟 #BreastCancer Abstracts to be presented at #ESMO25 in Berlin
Reposted by Gil Morgan MD
oncoalert.bsky.social
See you in Berlin for #ESMO25!
The OncoAlert AF is ready to bring you all the great science coming out of Germany🇩🇪 .

We encourage you to follow these outstanding colleagues, and—as always—OncoAlert will be on the ground reporting in real time on all the latest news and trials.
Reposted by Gil Morgan MD
oncoalert.bsky.social
A warm welcome to the 43rd Annual CFS, NOW VIRTUAL (LIVE OR ONLINE) !!
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) tinyurl.com/3ak6zm6s

A great 3 day conference for health care professionals focused on evidence-based, state-of-the-art cancer care. SIGN UP FOR FREE VIRTUAL REGISTRATION!
Reposted by Gil Morgan MD
oncoalert.bsky.social
NEWS FROM INDUSTRY: UPDATE ON TROPION-Breast02 #BreastCancer
Source European Pharmaceutical Review, Astrazeneca, Daiichi Sankyo

www.europeanpharmaceuticalreview.com/news/266702/...

The phase III TROPION-Breast02 trial showed that the ADC Datopotamab Deruxtecandlnk significantly improved OS & PFS
Reposted by Gil Morgan MD
oncoalert.bsky.social
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysis

www.sciencedirect.com/science/arti...
Reposted by Gil Morgan MD
oncoalert.bsky.social
The OncoAlert #GUCancer Faculty, led by Dr. Natalia Gandur🇦🇷 , Dr. Regina Barragan🇲🇽 & Dr. Gil Morgan🇺🇸 have selected the OncoAlert TOP🔟 #ESMO25 Abstracts In #ProstateCancer, #KidneyCancer #BladderCancer and #PenisCancer to be presented in Berlin🇩🇪 Picked using a Delphi System to establish our picks.
Reposted by Gil Morgan MD
oncoalert.bsky.social
A Great Day One of #IUCS25 Great Presentation by Dr. Partha Choudhury

The Theranostic Revolution
✨ Early randomized results look promising
🎯 Time to reimagine dosimetry & radionuclide choice for optimized delivery
#ProstateCancer
Reposted by Gil Morgan MD
oncoalert.bsky.social
A Great Day One of #IUCS25 Great Presentation by Dr. Sara Rebuzzi 🇮🇹

⏸️ Treatment Breaks in #KidneyCancer – Key Takeaways
✅ Feasible in selected patients, with potential for long-term disease control
✅ Reduced toxicity burden vs continuous therapy
📊 Stronger evidence with ICI than TKI
Reposted by Gil Morgan MD
oncoalert.bsky.social
Day2⃣of #IUCS25 🇬🇧Portsmouth
Dr. Enrique Grande 🇪🇸 discusses “Geting more patient the right 1st line in Bladder Cancer.”

👉 improving patient selection, refining dosing strategies, and developing predictive tools are key to making sure more patients receive and benefit the right first-line tx
Reposted by Gil Morgan MD
oncoalert.bsky.social
Day2⃣of #IUCS25 🇬🇧Portsmouth

Dr. Petros Grivas🇺🇸 discusses “How Perioperative Treatment is Evolving in Bladder Cancer.”

📌 The perioperative space in MIBC is rapidly transforming—biomarkers, immunotherapy, ADCs, and combinations are reshaping the standard of care.
Reposted by Gil Morgan MD
oncoalert.bsky.social
Experience the 2025 International Symposium of Gastrointestinal Oncology (ISGIO) LIVE in Austin Tx or Streamed ONLINE ! 👉 FREE HCP Registration (USE CODE: ONCOALERT )🚨
buff.ly/KVngjav

Join leading experts for two days of case-based learning, interactive panels, and cutting-edge updates in GI
Reposted by Gil Morgan MD
oncoalert.bsky.social
You're invited to watch the Post-ASCO 2025 Lung Cancer Highlights webinar by @VJOncology 🫁 Watch Here 👉 bit.ly/4o14fdK

Featuring expert presentations and in-depth discussions on key abstracts in #Lungcancer presented at ASCO 2025.
Reposted by Gil Morgan MD
oncoalert.bsky.social
Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma

www.sciencedirect.com/science/arti...

This international four-phase study (2022–2024) sought to modernize health-related quality of life (HRQOL) assessment tools
Reposted by Gil Morgan MD
oncoalert.bsky.social
Join Our Collaborators at @SpringerIME to explore this new, FREE clinical pathway tool designed to help you detect and target NTRK fusions🧬 & HER2 mutations in #NSCLC 🫁 #LungCancer

CLICK HERE👉https://buff.ly/FeMbJ0r
Reposted by Gil Morgan MD
oncoalert.bsky.social
Anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open-label, phase 1b clinical trial

acsjournals.onlinelibrary.wiley.com/doi/10.1002/...
Reposted by Gil Morgan MD
realbowtiedoc.bsky.social
@weoncologists.bsky.social summarizes the @oncoalert.bsky.social round-up 🤠

#SuppOnc dataon #GA the pillar assessment for #olderadults

#GIonc includes #agnostic treatments in #dMMR cancer 🧬

Be sure to not miss an update by signing up 🔗: oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
Reposted by Gil Morgan MD
oncoalert.bsky.social
The #ASCO25 #OncoAlertTOP10 Abstracts in #LungCancer 🫁 These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago 🇺🇸

@biagioricciutimd.bsky.social
@stephenvliu.bsky.social
@drsanjaypopat.bsky.social
Ping
@drjnaidoo.bsky.social
Reposted by Gil Morgan MD
oncoalert.bsky.social
The #ASCO25 #OncoAlertTOP10 Abstracts in GI Oncology
These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸

@realbowtiedoc.bsky.social
@arosen380.bsky.social
Ping
‪@gillsharlene.bsky.social‬
Reposted by Gil Morgan MD
realbowtiedoc.bsky.social
ascocancer.bsky.social
The most clinically relevant science in oncology will be presented at #ASCO25, and you can now view the full 5,000 abstracts & their presentation date, time & location info: brnw.ch/21wSRrH